TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32976088

Group type: EXPERIMENTAL
Intervention: DOM group performed a damaging eccentric exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON group rested
Number of subjects: 10
Study: 34014555

Group type: EXPERIMENTAL
Intervention: HLX04
Number of subjects: 677

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 677
Study: 36228963

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 1836

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1836
Study: 32494976

Group type: EXPERIMENTAL
Intervention: Diabetes education plus stress management and relaxation training (DE + SMR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diabetes education only (DE-only)
Number of subjects: 50
Study: 35714315

Group type: EXPERIMENTAL
Intervention: One course of delayed intensification in low-risk group
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Two delayed intensifications in low-risk group
Number of subjects: 3113

Group type: COMPARATOR
Intervention: Standard therapy in high-risk group
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Augmented therapy in high-risk group
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Augmented therapy in cytogenetic high-risk patients
Number of subjects: 3113

Group type: COMPARATOR
Intervention: Standard therapy in cytogenetic high-risk patients
Number of subjects: 3113
Study: 32545655

Group type: EXPERIMENTAL
Intervention: CC + HF group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: CC + MF group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: T + HF group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: T + MF group
Number of subjects: 220
Study: 35926882

Group type: EXPERIMENTAL
Intervention: Direct Lateral (DL) approach with collared femoral stem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct Lateral (DL) approach with collarless femoral stem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct Anterior (DA) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (DL and DA)
Number of subjects: 0
Study: 33341707

Group type: EXPERIMENTAL
Intervention: Medium dose nab-paclitaxel (MD220) 220 mg/m2
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Low dose nab-paclitaxel (LD180) 180 mg/m2
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard dose nab-paclitaxel (SD260) 260 mg/m2
Number of subjects: 141
Study: 32957959

Group type: COMPARATOR
Intervention: Standard education condition (information about benefits)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Planning (action planning, coping planning) + education condition
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Habit (context-dependent repetition from prompts and cues) + planning + education condition
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Parental co-activity habit, parent-child co-activity, and other behavioral constructs
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Parental PA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Co-activity
Number of subjects: 150
Study: 36072931

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100mg per day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Metformin (500mg three times per day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sitagliptin plus Metformin (100mg sitagliptin and 500mg metformin three times per day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 68
Study: 32828880

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 450

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 450
Study: 33144278

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34579068

Group type: EXPERIMENTAL
Intervention: Probiotics (MCP® BCMC® strains) for 6 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 39
Study: 32386720

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Efavirenz (600 mg each night)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 408

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 408
Study: 36309743

Group type: EXPERIMENTAL
Intervention: Transvaginal natural orifice specimen extraction (NOSE)
Number of subjects: 38
Study: 34118179

Group type: EXPERIMENTAL
Intervention: Pirepemat 350 mg single dose
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pirepemat 100 mg multiple doses (3 times daily for 7 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pirepemat 250 mg multiple doses (3 times daily for 7 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pirepemat (all doses)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Food intake
Number of subjects: 44
Study: 32113625

Group type: COMPARATOR
Intervention: Monetary incentive of 10 SGD for completing a questionnaire
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Monetary incentive of 20 SGD for completing a questionnaire and vaccination
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Monetary incentive of 30 SGD for completing a questionnaire and vaccination
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Monetary incentive of 10 SGD for completing a questionnaire and vaccination
Number of subjects: 4000
Study: 35184101

Group type: EXPERIMENTAL
Intervention: Digitally fabricated removable dental prostheses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventionally manufactured removable dental prostheses
Number of subjects: 0
Study: 33248884

Group type: EXPERIMENTAL
Intervention: Application of consistency/inconsistency flags to PSP ratings
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Application of flags to clinical ratings
Number of subjects: 18000
Study: 35862774

Group type: EXPERIMENTAL
Intervention: Centrally procured school food program
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Children's fruit and vegetable consumption
Number of subjects: 2443
Study: 33904966

Group type: EXPERIMENTAL
Intervention: Multidomain cognitive training (CT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low-intensity physical activity training (PT)
Number of subjects: 64
Study: 35348246

Group type: EXPERIMENTAL
Intervention: Prediction model for postoperative severe ALI based on variables including coronary heart disease, cardiopulmonary bypass (CPB) ≥ 257.5 min, left atrium diameter ≥ 35.5 mm, hemoglobin ≤ 139.5 g/L, preCPB OI ≤ 100 mmHg, intensive care unit OI ≤ 100 mmHg, left ventricular posterior wall thickness ≥ 10.5 mm, neutrophilic granulocyte percentage ≥ 0.824.
Number of subjects: 479
Study: 32640940

Group type: EXPERIMENTAL
Intervention: Goal-Directed Hemodynamic Therapy (GDHT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard Clinical Care (Control)
Number of subjects: 108
Study: 36435732

Group type: EXPERIMENTAL
Intervention: GLS-guided cardioprotection (CPT)
Number of subjects: 331

Group type: COMPARATOR
Intervention: EF-guided cardioprotection (CPT)
Number of subjects: 331
Study: 33880884

Group type: EXPERIMENTAL
Intervention: Foot massage for 3 minutes with baby oil
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (waiting for 3 minutes)
Number of subjects: 128
Study: 32931044

Group type: EXPERIMENTAL
Intervention: Fingers
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Left fingers and feet
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Left fingers and wrists
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Left fingers and shoulders
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Left fingers and calves
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lower body
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Fingers and feet
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Wrists
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Repeatability investigation
Number of subjects: 115
Study: 33198533

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 agency assignment
Number of subjects: 207

Group type: COMPARATOR
Intervention: Human agency assignment
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Reference point (self/self-other)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Interaction between agency assignment and reference point
Number of subjects: 207
Study: 32597617

Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stretching on Whole-Body Vibration (WBV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 24
Study: 36380306

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg starting 12 hours after surgery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Unilateral portable IPCD used 24 hours/day on the operated leg for 10 days
Number of subjects: 150
Study: 32070335

Group type: EXPERIMENTAL
Intervention: HbA1c < 6.5%
Number of subjects: 1328

Group type: COMPARATOR
Intervention: HbA1c 7.0-7.5%
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: HbA1c 6.5-7.0%
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: HbA1c 7.5-8.5%
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 8.5%
Number of subjects: 1328
Study: 35696684

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 1600

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia and General anesthesia
Number of subjects: 1600
Study: 33852204

Group type: EXPERIMENTAL
Intervention: Initial triple therapy with metformin, pioglitazone, and exenatide
Number of subjects: 104

Group type: COMPARATOR
Intervention: Stepwise conventional therapy with metformin followed by glipizide and then glargine insulin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CPEP120/CPEP0 ratio of more than 1.7
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CPEP120/CPEP0 of less than 1.7 plus FPG of 269 mg/dL or less
Number of subjects: 104
Study: 32392422

Group type: EXPERIMENTAL
Intervention: Water to maintain hydration
Number of subjects: 11

Group type: COMPARATOR
Intervention: No fluid (1.7% ± 0.3% body mass loss)
Number of subjects: 11
Study: 33511963

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 785
Study: 32176392

Group type: EXPERIMENTAL
Intervention: Incremental theory group (IT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Incremental theory plus success criteria group (IT + SC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 35839791

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (1.5 g cefuroxime, intramuscular in Norway or intravenous in Germany)
Number of subjects: 555

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 555
Study: 35549505

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 33032837

Group type: EXPERIMENTAL
Intervention: Mediterranean Portfolio Diet (Diet2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low saturated fat diet (Diet1)
Number of subjects: 60
Study: 35880252

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery with fast-acting insulin aspart
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard insulin therapy (control group)
Number of subjects: 45
Study: 33763879

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking combined with jogging) for 60 minutes per day, 5 days a week for 8 weeks
Number of subjects: 60
Study: 32695815

Group type: EXPERIMENTAL
Intervention: Gelatin-thrombin matrix sealant (GTMS)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (no GTMS)
Number of subjects: 206
Study: 33856856

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy
Number of subjects: 224

Group type: COMPARATOR
Intervention: Brief psychosocial intervention
Number of subjects: 224
Study: 32072651

Group type: EXPERIMENTAL
Intervention: Nurses' empathic tendencies
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Nurses' empathic skills
Number of subjects: 472
Study: 35954810

Group type: EXPERIMENTAL
Intervention: Hybrid cardiovascular rehabilitation program (first 5 days in rehabilitation centre, then in sport centres)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional rehabilitation program in a rehabilitation centre
Number of subjects: 60
Study: 34726850

Group type: COMPARATOR
Intervention: Astra Tech implants (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Brånemark implants (group B)
Number of subjects: 18
Study: 32833481

Group type: EXPERIMENTAL
Intervention: WLM + EFT
Number of subjects: 0

Group type: COMPARATOR
Intervention: WLM-STD
Number of subjects: 0
Study: 36436017

Group type: EXPERIMENTAL
Intervention: SSSH (Structured Supervised Strength Training)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Walk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 32331076

Group type: EXPERIMENTAL
Intervention: Esketamine (ESK) + oral antidepressant (AD)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Oral antidepressant (AD) + intranasal placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PHQ‐9 items #1, #2, #4, #6
Number of subjects: 176
Study: 35167059

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 33226186

Group type: EXPERIMENTAL
Intervention: Blood pressure variability (BPV) measurements during the subacute phase
Number of subjects: 832
Study: 35545446

Group type: EXPERIMENTAL
Intervention: ACE‐083 (240 mg/muscle injected bilaterally in the tibialis anterior muscle)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ACE‐083
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 34157878

Group type: EXPERIMENTAL
Intervention: Beyond Violence (BV) program, 20 sessions
Number of subjects: 145

Group type: COMPARATOR
Intervention: Waitlist control (WC)
Number of subjects: 145
Study: 32780476

Group type: EXPERIMENTAL
Intervention: Biphasic pulses with phase durations (PD) 200µs and an interphase interval (IPI) of 200µs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Biphasic pulses with phase durations (PD) 500µs and an interphase interval (IPI) of 200µs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Monophasic pulses with phase duration (PD) 200µs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Biphasic pulses with phase durations (PD) 200µs or 500µs without an IPI
Number of subjects: 18
Study: 36403124

Group type: EXPERIMENTAL
Intervention: Orthopedic RCTs assessing balancing
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Statistical significance testing for baseline characteristics
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Primary outcome measures (PROMs)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Baseline PROM values reported
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Difference in baseline PROM values between groups
Number of subjects: 86
Study: 33010116

Group type: EXPERIMENTAL
Intervention: Ketone monoester (KM) ingestion
Number of subjects: 9
Study: 32989872

Group type: EXPERIMENTAL
Intervention: Spironolactone-pioglitazone-metformin (SPIOMET)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (age-matched girls)
Number of subjects: 30
Study: 32299024

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 36008143

Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg for 10 days)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 34187420

Group type: EXPERIMENTAL
Intervention: Telemedical care including regular, individualized telephone calls and SMS-messages
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 118
Study: 33543476

Group type: EXPERIMENTAL
Intervention: Greater palatine compression suture (GPCS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 32571277

Group type: EXPERIMENTAL
Intervention: Private facilities
Number of subjects: 300

Group type: COMPARATOR
Intervention: Public facilities
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Out-of-pocket healthcare expenditure ≥USD 30
Number of subjects: 300

Group type: COMPARATOR
Intervention: Out-of-pocket healthcare expenditure ≤USD 5
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Male-headed households
Number of subjects: 300

Group type: COMPARATOR
Intervention: Female-headed households
Number of subjects: 300
Study: 35908042

Group type: EXPERIMENTAL
Intervention: 2 mA tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 32926748

Group type: EXPERIMENTAL
Intervention: Irsogladine maleate (IM) 4 mg/day for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Irsogladine maleate (IM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-administration group
Number of subjects: 24
Study: 32810748

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: FBXW7 mutations
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: MSI-H tumours
Number of subjects: 373
Study: 36004519

Group type: EXPERIMENTAL
Intervention: Educational intervention (120-minute sessions once a week for four weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 64
Study: 33990648

Group type: EXPERIMENTAL
Intervention: Tria Ureteral Stent
Number of subjects: 84

Group type: COMPARATOR
Intervention: Polaris Ultra Ureteral Stent
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clinical factors
Number of subjects: 84
Study: 32546554

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg daily as maintenance therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 34010934

Group type: COMPARATOR
Intervention: Topical estrogen therapy (n=12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy (n=13)
Number of subjects: 25
Study: 35543701

Group type: EXPERIMENTAL
Intervention: Alirocumab (PCSK9 inhibitor)
Number of subjects: 11880

Group type: EXPERIMENTAL
Intervention: Creatine kinase levels during statin treatment
Number of subjects: 11880

Group type: EXPERIMENTAL
Intervention: p.Val174Ala (rs4149056) in SLCO1B1
Number of subjects: 11880
Study: 32299241

Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA) plus electroacupuncture (EA) for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture (sham MA plus sham EA) for 6 weeks
Number of subjects: 120
Study: 32122325

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and cognitive training (EXCOG)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cognitive training (COG)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Video-watching control (CON)
Number of subjects: 74
Study: 35757477

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Phentolamine + Lidocaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 66
Study: 32419559

Group type: EXPERIMENTAL
Intervention: Biotin supplementation prescribed by physicians
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Other biotin-containing supplements recommended by physicians
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Knowledge of randomized studies on biotin
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Knowledge of biotin interference with laboratory tests
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Awareness of biotin interference with other tests
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Physicians asking patients to discontinue biotin before testing
Number of subjects: 149
Study: 33439250

Group type: EXPERIMENTAL
Intervention: Surgical treatment (open reduction and internal fixation using a volar-locking plate)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Nonsurgical treatment (closed reduction and cast immobilization)
Number of subjects: 166
Study: 35331961

Group type: EXPERIMENTAL
Intervention: Exercise training (HFAF‐trained group; n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No training (HFAF‐untrained group; n = 13)
Number of subjects: 26
Study: 32615637

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 0
Study: 34435205

Group type: EXPERIMENTAL
Intervention: Radiomics score based on pericoronary adipose tissue (PCAT)
Number of subjects: 1586

Group type: COMPARATOR
Intervention: Plaque score based on conventional plaque characteristics
Number of subjects: 1586

Group type: EXPERIMENTAL
Intervention: Integrated score
Number of subjects: 1586
Study: 35019219

Group type: EXPERIMENTAL
Intervention: 4-mm ultrashort implants
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10-mm long implants in augmented bone
Number of subjects: 80
Study: 32646563

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus- and probucol-eluting stents
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Durable polymer zotarolimus-eluting stents
Number of subjects: 3002
Study: 35357606

Group type: EXPERIMENTAL
Intervention: CultActive treatment (A23187 ionophore), 122 MII oocytes treated
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (no treatment), 125 MII oocytes
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: CultActive treatment (A23187 ionophore)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 247